knowledge -WSS

knowledge

author：leisure time 2025-09-03 12:10:42 - browse：63

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： VC firm RA Capital starts a new synthetic biology incubator

WSS

‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Interest rates are at a 22

With psoriasis trial ahead, Alumis raises $259 million

The mammogram wars are not over

leisure time

knowledge

focus

Cancer drug shortages should be causing more outrage

Ending health disparities requires full federal government, panel says

Drug repurposing or repositioning? The language matters

RSV shot was 90% effective at preventing hospitalizations in kids

Medical leaders decry Supreme Court decision on affirmative action

Will biotech layoffs continue through 2023?

Anesthesiologist group: stop taking Ozempic before surgery

Biden to sign 'historic' executive order on how US military handles sexual assault cases

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

Wikipedia

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

'The boss' wants server deleted: New allegations emerge in Trump indictment

Interest rates are at a 22

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Sen. Paul opposes bill to ban Chinese biotechs

knowledge

entertainment

explore

knowledge